Evidence & regulatory context
- Mechanism
- Biologic (platelet factor 4 / CXCL4 chemokine); not a discrete ChEMBL drug; found only as a biomarker in trials
- Target
- Not recorded
- Injury models
- Radiation
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseRadiationC57BL/6Male
Model: Gamma-irradiation of bone marrow mesenchymal stem cells at 500 cGy, studied ex vivo and in vitro
Platelet factor 4 produced dose- and time-dependent increases in cell viability and survival with reduced apoptosis, S phase arrest, increased Bcl-2 and loss of p53/p21.
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
